Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Neuroblastoma
Stage/Subtype:  recurrent neuroblastoma
Trial Type:  Treatment
Results 1-25 of 48 for your search:
Start Over
Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients
Status: Active
Phase: Phase IV
Type: Natural history/Epidemiology, Treatment
Age: 1 to 18
Trial IDs: DIV-NB-401, NCI-2016-00676, NCT02693171
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 17 months and under
Trial IDs: ANBL1232, NCI-2014-00677, NCT02176967
OPT-821 with Vaccine Therapy and Beta-Glucan in Treating Younger Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: 05-075, NCI-2009-01362, NCT00911560
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 21 years
Trial IDs: ABI-007-PST-001, NCI-2015-00737, NCT01962103
WEE1 inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients with Relapsed or Refractory Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1312, NCI-2014-00547, NCT02095132
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: NMTRC010, NCI-2015-01871, NCT02139397
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Nivolumab with or without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: ADVL1412, NCI-2014-01222, NCT02304458
Iobenguane I-131 in Treating Patients with Recurrent Neuroblastoma, Malignant Pheochromocytoma or Malignant Paraganglioma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 1
Trial IDs: 04-148, NCI-2016-00955, MSKCC-04148, NCT00107289
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Any age
Trial IDs: 05-122, NCI-2016-00874, MSKCC-05122, NCT00445965
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: V0706, NCI-2014-00478, NCT00601003
Irinotecan Hydrochloride and Temozolomide with Temsirolimus or Dinutuximab in Treating Younger Patients with Refractory or Relapsed Neuroblastoma
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Children
Trial IDs: ANBL1221, NCI-2012-03125, CDR0000745188, COG-ANBL1221, PANBL1221_A08PAMDREVW01, NCT01767194
Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 0 to 40
Trial IDs: J12106, NCI-2013-00702, CIR00008429, CIR00009228, NA_00076243, NA_00076243 / CIR00009228, NCT01804634
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 18
Trial IDs: 116731, NCI-2015-00058, NCT01956669
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 24 months to less than 30 years
Trial IDs: N2011-01, NCI-2015-00640, NCT02035137
Proton Beam Radiation Therapy in Treating Patients with Neuroblastoma or Ganglioneuroblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 3 to 25
Trial IDs: 13-443, NCI-2014-01557, NCT02112617
Lorvotuzumab Mertansine in Treating Younger Patients with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 30 years
Trial IDs: ADVL1522, NCI-2015-00746, NCT02452554
T-cell Depleted Stem Cell Boost in Improving Graft Function in Patients Who Have Undergone Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 14-228, NCI-2015-00179, NCT02350777
Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and/or Refractory Solid or Central Nervous System Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 months to 30 years
Trial IDs: AFLACST1502, NCI-2015-01637, IRB00082488, NCT02574728
Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Recurrent or Refractory Tumors in the Brain and/or Spinal Cord
Status: Active
Phase: Phase I
Type: Treatment
Age: Any age
Trial IDs: 03-133, NCI-2016-00928, MSKCC-03133, NCT00089245
Monoclonal Antibody Therapy in Treating Younger Patients with Relapsed or Refractory Neuroblastoma, Osteosarcoma, or Melanoma
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 21
Trial IDs: SJGD2, NCI-2011-01150, ED FDN, NCT00743496
Donor Natural Killer Cells and Monoclonal Antibody 3F8 after Combination Chemotherapy in Treating Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase I
Type: Treatment
Age: Not specified
Trial IDs: 09-011, NCI-2009-01378, MSKCC-09001, NCT00877110
Vorinostat and Iobenguane I 131 in Treating Patients With Resistant or Relapsed Neuroblastoma
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 30
Trial IDs: NANT 2007-03, NCI-2009-01450, NANT-N2007-03, N2007-03, NCT01019850
Start Over